What is Zacks Research’s Estimate for Prothena Q1 Earnings?

Prothena Corporation plc (NASDAQ:PRTA) – Equities researchers at Zacks Research increased their Q1 2026 EPS estimates for shares of Prothena in a research report issued on Thursday, September 11th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.88) per share for the quarter, up from their previous forecast of ($0.92). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($2.59) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.80) EPS and FY2027 earnings at ($1.93) EPS.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The firm had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million.

A number of other equities analysts have also weighed in on PRTA. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Prothena in a research note on Friday, June 20th. Chardan Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of Prothena in a research note on Thursday, August 28th. Jefferies Financial Group lowered shares of Prothena from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a research note on Tuesday, May 27th. Bank of America reissued an “underperform” rating on shares of Prothena in a research report on Wednesday, May 28th. Finally, JMP Securities cut their price target on shares of Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.75.

Prothena Trading Down 2.6%

Shares of NASDAQ PRTA opened at $8.21 on Monday. The firm has a market cap of $441.94 million, a PE ratio of -1.46 and a beta of -0.04. Prothena has a 1-year low of $4.32 and a 1-year high of $22.71. The company has a fifty day moving average price of $7.53 and a 200 day moving average price of $8.48.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRTA. Deutsche Bank AG grew its position in shares of Prothena by 195.7% during the 4th quarter. Deutsche Bank AG now owns 95,970 shares of the biotechnology company’s stock worth $1,329,000 after purchasing an additional 63,512 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Prothena during the 1st quarter worth approximately $126,000. SG Americas Securities LLC grew its position in shares of Prothena by 92.9% during the 1st quarter. SG Americas Securities LLC now owns 72,559 shares of the biotechnology company’s stock worth $898,000 after purchasing an additional 34,947 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Prothena by 29.5% during the 4th quarter. ProShare Advisors LLC now owns 14,524 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 3,312 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 5,875 shares in the last quarter. 97.08% of the stock is owned by institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.